THERALINK_LO_FF_BLUE.png
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
18 déc. 2023 09h15 HE | Theralink Technologies, Inc.
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse...
SeaStar_SM_LogoCard.png
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
09 janv. 2023 08h25 HE | SeaStar Medical Holding Corporation
Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) --...